The abstract is read at the publisher; the summary is JClub's.
Glofitamab-based therapy in 84 consecutive patients with relapsed or refractory CNS lymphoma produced high response rates, with PCNSL ORR 88% and CRR 59%.
- Why it matters: Relapsed or refractory CNS lymphoma has limited options, so clinicians need evidence on efficacy and safety to guide treatment for this high-risk population.
- What they did: In a multicenter retrospective cohort, 84 patients (53 PCNSL, 31 SCNSL) received glofitamab monotherapy or combination therapy, and outcomes included ORR, CRR, progression-free survival, and toxicity.
- The result: With 14.7 months of follow-up, median progression-free survival was 19.5 months for PCNSL; cytokine release syndrome occurred in 40% (grades 1–2) and neurotoxicity in 8%.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.